Ovoca Bio PLC - Annual Financial Report
Ovoca Bio plc
("Ovoca" or the "Company")
Publication of 2023 Annual Report
http://www.rns-pdf.londonstockexchange.com/rns/2362U_1-2024-6-27.pdf
2023 Highlights:
During 2023, the Ovoca management team focused on the following key areas:
· Analysis of the data and results from the Phase II dose ranging study assessing Orenetide in
· Disposal of Russian assets and optimization of corporate structure - the ongoing sanctions pressure around the Russian economy and financial system required significant work to be completed during the year, including the disposal of certain Russian assets which the Company announced in
· Ensuring the Company has sufficient funding to cover its expenditure as required.
Letter from the CEO
We are pleased to today publish the 2023 Full Year Annual report for Ovoca.
At the beginning of the reporting period - 2023 - the main efforts of the Company were focused on the active development of Orenetide. It is not surprising that the events which occurred at the beginning of the 3rd quarter 2023 - the results of a Clinical Trial conducted in
It should be noted that the primary focus of the Company in recent years was based on the expectation of success with the Australian and NZL Study. Therefore, all management efforts with partners and contractors were aimed to allow fast progression after receiving the expected positive results of the Study, and the financial strategy of the Company had been framed to ensure a sufficient margin of liquidity at that time.
However, receiving negative Study results was a turning point in the Company's endeavours to pursue previous strategic goals in the biopharma sector. We have made a lot of efforts to comprehensively, thoroughly and deeply analyse the root causes of the Study failure and understand whether there are prospects for further development of Orenetide.
Unfortunately, following further analysis, we have decided that further research and development activities in relation to Orenetide do not make sense in the current environment and we have therefore paused development plans for the asset. This is immediately reflected in the re-valuation of the Company's Intangible Assets, as presented in the 2023 Annual Report. However, significant efforts have been made to maintain the financial stability of the Company, taking into account Ovoca's contracts and obligations. Such stability will allow for a reassessment of the Company's strategic prospects, focusing on minimizing losses for shareholders and finding a potentially profitable new path.
Significant work has been done to improve the Company's corporate structure and this work is ongoing. We are progressing analysis to execute on the planned disposal or reorganisation of the Company's assets historically located in complicated jurisdictions, while also seeking the settlement of litigation regarding Taymura . Taken together, this is a rather long and difficult process, not helped by the ongoing turbulence in the world and the ever-tightening mutual sanctions pressure between the main jurisdictions of the Company's assets. However, we expect that this work will bear fruit in the current year and make the Company better positioned in terms of potential strategic business opportunities.
Thus, the current efforts of management and Directors are focused on investigating strategic business opportunities, where current internal skillsets and competencies can be best used to benefit the Company.
In concluding my statement, I would like to take this opportunity to thank the management of the Company and the members of the Board of Directors for their perseverance, hard work despite all difficulties and invaluable contribution to the further development of Ovoca.
Annual Report
The Annual Report and Financial Statements will shortly be posted to shareholders and are also available online at the Company's website, www.ovocabio.com.
End
For further information:
Ovoca Bio plc
Tel +353 1 661 9819
Davy (Nominated Adviser, Euronext Growth Listing Sponsor and Broker)
Tel: +353 1 679 6363
About Ovoca Bio
Ovoca Bio is a European-based biopharmaceutical company with a focus on women's health. The Company's lead product, Orenetide, a novel synthetic peptide administered through a nasal spray, that had demonstrated statistically significant improvement in a number of symptoms associated with HSDD in the previous clinical trials, recently has failed to demonstrate treatment benefit over control group in the Phase II study conducted in
Following these Study results, the Company has suspended further R&D plans for Orenetide and is investigating potential strategic opportunities for the business.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE